对于非阻塞性多变性心肌病和心力衰竭患者的心脏再同步的加速巴赫曼捆区域节奏:一个随机交叉试验
Muthiah Subramanian1, Sachin Yalagudri1, Daljeet Kaur Saggu1
1AIG Institute of Cardiac Sciences, Hyderabad, Telangana, India.
Heart rhythm
|July 27, 2025
概括
加快巴赫曼捆区域节奏 (BBAP) 改善了非阻塞性多变性心肌病和心房间隔阻塞的患者的心力衰竭症状. 这种节奏策略降低了NT-proBNP水平,提高了运动能力.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 心脏衰竭研究研究
背景情况:
- 间阻塞 (IAB) 在心力衰竭中加剧了心脏失调功能,并保留了喷射分数 (HFpEF).
- 非阻塞性缩性心肌病 (nHCM) 在管理HFpEF和相关导电异常 (如IAB) 方面存在独特的挑战.
研究的目的:
- 评估加快巴赫曼捆区域节奏 (BBAP) 在患有nHCM,HFpEF和IAB的症状患者的疗效.
- 为了比较BBAP对临床和生化标志物的效果,使用标准节奏和没有节奏.
主要方法:
- 一项前性,随机的,患者盲目的交叉研究,涉及42名患有nHCM,HFpEF和IAB的患者.
- 患者接受了双室植入式心脏转换器除器植入,并获得了成功的BBAP.
- 干预包括4周的BBAP (DDDR 70/分钟) 与没有节奏 (VVI 30/分钟),然后进行交叉,并与使用右心房附属体节奏 (RAAP) 的历史队列进行比较.
主要成果:
- 与没有节拍 (P = .008) 和RAAP (P = .021) 相比,BBAP显著降低了N-终端前脑尿素 (NT-proBNP) 水平.
- 在二次终点中观察到改善,包括6分钟的步行距离,功能类,透静填充参数和减少每日尿剂需求.
- 与RAAP相比,BBAP在减少NT-proBNP和改善二次终点方面显示出更好的结果.
结论:
- 加速BBAP是一种有效的策略,用于管理患有nHCM,HFpEF和IAB的患者.
- 在这种患者群体中,BBAP会导致NT-proBNP的显著减少,改善腹功能和增强运动能力.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
52
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52
Dysrhythmias IV: Characteristics of Bradyarrhythmias
120
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
120
Disturbances in Heart Rhythm
1.3K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.3K
Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
Dysrhythmias VI: Management of Dysrhythmias
107
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
107


